These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 31299882

  • 1. Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina.
    Scolnik M, Scaglioni V, Pons-Estel GJ, Soriano ER.
    Lupus; 2019 Aug; 28(9):1167-1173. PubMed ID: 31299882
    [Abstract] [Full Text] [Related]

  • 2. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 3. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort.
    Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB, Wojdyla D, Pons-Estel GJ, Quintana R, Esposto A, García MA, Catoggio LJ, Cardiel MH, Barile LA, Amigo MC, Sato EI, Bonfa E, Borba E, Lavras Costallat LT, Neira OJ, Massardo L, Guibert-Toledano M, Chacón-Díaz R, Alarcón GS, Pons-Estel BA.
    Lupus; 2019 Aug 20; 28(9):1101-1110. PubMed ID: 31291843
    [Abstract] [Full Text] [Related]

  • 4. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.
    Arthritis Care Res (Hoboken); 2017 Jan 20; 69(1):115-123. PubMed ID: 27390293
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.
    Babini A, Cappuccio AM, Caprarulo C, Casado G, Eimon A, Figueredo H, García MA, Magri S, Mannucci P, Perez Rodriguez S, Pons-Estel BA, Velozo EJ, Iglesias-Rodriguez M, Streger G.
    Lupus; 2020 Oct 20; 29(11):1385-1396. PubMed ID: 32791930
    [Abstract] [Full Text] [Related]

  • 6. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.
    Lupus; 2010 Feb 20; 19(2):213-9. PubMed ID: 19965944
    [Abstract] [Full Text] [Related]

  • 7. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A.
    Arthritis Rheumatol; 2020 Aug 20; 72(8):1314-1324. PubMed ID: 32275125
    [Abstract] [Full Text] [Related]

  • 8. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR.
    BMJ Open; 2019 Dec 16; 9(12):e032569. PubMed ID: 31848169
    [Abstract] [Full Text] [Related]

  • 9. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
    Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S.
    Rheumatol Int; 2017 Jun 16; 37(6):865-873. PubMed ID: 28280970
    [Abstract] [Full Text] [Related]

  • 10. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.
    Semin Arthritis Rheum; 2018 Dec 16; 48(3):467-474. PubMed ID: 29555348
    [Abstract] [Full Text] [Related]

  • 11. Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey.
    Balci S, Ekinci RMK, Bayazit AK, Melek E, Dogruel D, Altintas DU, Yilmaz M.
    Clin Rheumatol; 2019 May 16; 38(5):1459-1468. PubMed ID: 30648229
    [Abstract] [Full Text] [Related]

  • 12. Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients.
    Reátegui-Sokolova C, Rodríguez-Bellido Z, Gamboa-Cárdenas RV, Medina M, Zevallos F, Pimentel-Quiroz VR, Elera-Fitzcarrald C, Cucho-Venegas M, Pastor-Asurza CA, Perich-Campos R, Alarcón GS, Ugarte-Gil MF.
    Lupus; 2019 Oct 16; 28(11):1344-1349. PubMed ID: 31551028
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
    von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger PM, Vallelian F, Schaer DJ, Mueller RB.
    Swiss Med Wkly; 2019 Feb 25; 149():w20022. PubMed ID: 30852830
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.
    Simonetta F, Allali D, Roux-Lombard P, Chizzolini C.
    Joint Bone Spine; 2017 Mar 25; 84(2):235-236. PubMed ID: 27238199
    [No Abstract] [Full Text] [Related]

  • 15. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR, Gordon C.
    BioDrugs; 2013 Apr 25; 27(2):85-95. PubMed ID: 23456653
    [Abstract] [Full Text] [Related]

  • 16. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort.
    González-Echavarri C, Capdevila O, Espinosa G, Suárez S, Marín-Ballvé A, González-León R, Rodríguez-Carballeira M, Fonseca-Aizpuru E, Pinilla B, Pallarés L, Ruiz-Irastorza G, RELES, Autoimmune Diseases Study Group GEAS.
    Lupus; 2018 Dec 25; 27(14):2253-2261. PubMed ID: 30451641
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis.
    Li H, Chen C, Yang H, Tu J.
    Eur J Pediatr; 2024 Sep 25; 183(9):3987-3995. PubMed ID: 38940925
    [Abstract] [Full Text] [Related]

  • 18. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A, Porta S, Ríos R, Martinez-Zapico A, Ortego-Centeno N, Agesta N, Ruiz-Irastorza G.
    Lupus; 2018 Sep 25; 27(10):1718-1722. PubMed ID: 29635998
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
    Fan Q, Yang H, Liu Y.
    Z Rheumatol; 2024 Jun 25; 83(5):387-392. PubMed ID: 38157053
    [Abstract] [Full Text] [Related]

  • 20. Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients.
    Andreoli L, Reggia R, Pea L, Frassi M, Zanola A, Cartella S, Franceschini F, Tincani A.
    Isr Med Assoc J; 2014 Oct 25; 16(10):651-3. PubMed ID: 25438460
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.